Floatz logo

Clenbuterol

Pompe Disease

Dwight Koeberl, M.D., Ph.D.Small moleculePhase 1/2Dormant
CCC
50/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
89/ 100

Competitive context

9 Active assets in the Pompe Disease cohort.

Asset / SponsorPhaseRating
Avalglucosidase Alfa
Genzyme, a Sanofi Company
Phase 4A
Avalglucosidase Alfa
Genzyme, a Sanofi Company
Phase 4A
Alglucosidase Alfa
Erasmus Medical Center
Phase 4A
Albuterol
National Taiwan University Hospital
Phase 4BBB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
University of Florida
Phase 4BB

View all 28 →

Same molecule, other indications

Clenbuterol is also rated in:

Mild Cognitive Impairment, Lewy Body Dementia, Parkinson's Disease Rapid Eye Movement Sleep Behavior Disorder, Parkinson's Disease DementiaDormant
B
Indicative ·
57 / 100
View asset →
amyotrophic lateral sclerosisDormant
CCC
Indicative ·
54 / 100
View asset →
type 2 diabetes mellitusDormant
CCC
Indicative ·
54 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →